Abstract: The method is based on the use of expression vectors coding for the sense and anti-sense mRNA of the Phase I and Phase II drug biotransformation enzymes showing a greatest variability in humans for transforming cells expressing reductase activity. Such vectors can modulate (increase or decrease) the individualized expression of an enzyme without affecting the other enzymes. This singular cell model can reproduce in vitro the metabolic idiosyncrasy of humans. It is applicable in the study of development of new drugs, specifically in the study of metabolism, potential idiosyncratic hepatotoxicity, medicament interactions, etc., of new drugs.
Type:
Application
Filed:
July 1, 2011
Publication date:
February 9, 2012
Applicant:
ADVANCED IN VITRO CELL TECHNOLOGIES, S.L.
Inventors:
JOSÉ VICENTE CASTELL RIPOLL, MARÍA JOSÉ GÓMEZ-LECHÓN, RAMIRO JOVER ATIENZA, AGUSTÍN LAHOZ RODRÍGUEZ
Abstract: The present invention relates to a box for transporting samples, conceived to maintain the temperature in its interior in a range between 15° C. and 25° C. for an extended time period and suitable for any product that requires thermal and mechanical resistance, particularly for biological samples. The transport box of the invention comprises a series of non-primary packaging of carefully selected dimensions, shape and materials, accumulating heat elements and, optionally, filling material.
Type:
Application
Filed:
July 28, 2009
Publication date:
February 18, 2010
Applicant:
ADVANCED IN VITRO CELL TECHNOLOGIES, S.L.
Abstract: The invention is aimed at nanoparticulate systems for the controlled release of heparin. It is specifically aimed at nanoparticulate systems comprising chitosan, heparin and optionally a polyoxyethylenated derivative, and which are ionically cross-linked, as well as being aimed at processes for obtaining them.
Type:
Application
Filed:
October 13, 2006
Publication date:
December 25, 2008
Applicant:
ADVANCED IN VITRO CELL TECHNOLOGIES, S.L.
Inventors:
Ana Isabel Vila Pena, Silvia Suarez Luque, Ma Jose Alonso Fernandez
Abstract: A cell model is disclosed that has a phenotypic profile, expressing at least one drug biotransformation enzyme. This model includes a cell having cytochrome reductase activity, transformed with at least one expression vector comprising a DNA sequence for a drug biotransformation enzyme. The method is based on the use of expression vectors coding for the sense and anti-sense mRNA of the Phase I and Phase II drug biotransformation enzymes showing a greatest variability in humans for transforming cells expressing cytochrome reductase activity. Such vectors can modulate (increase or decrease) the individualised expression of an enzyme without affecting the other enzymes. This cell model can reproduce in vitro the metabolic idiosyncrasy of humans. It is applicable in the study of development of new drugs, specifically in the study of metabolism, potential idiosyncratic hepatotoxicity, medicament interactions, etc., of new drugs.
Type:
Application
Filed:
February 10, 2004
Publication date:
August 11, 2005
Applicant:
ADVANCED IN VITRO CELL TECHNOLOGIES, S.L.
Inventors:
Jose Castell Ripoll, Ramiro Atienza, Maria Gomez Lechon